387: Challenges for a crucial sickle cell treatment and the latest outlook for GLP-1s

What It Covers

This episode examines three major biotech developments: Novo Nordisk forecasts sales decline while Eli Lilly projects 23-27% growth in GLP-1 obesity drugs, Compass Pathways' psychedelic depression treatment gets removed from Trump's priority voucher program, and Vertex's CRISPR sickle cell therapy Kascevi faces severe manufacturing delays due to difficult stem cell collection.

Key Questions Answered

• •GLP-1 Market Divergence: Novo Nordisk forecasts 5-13% sales decline versus analyst expectations of 3% decline, while Eli Lilly projects 23-27% growth and added nearly $100 billion in market cap in one day. Lilly's Zepbound shows superior effectiveness and gains market share, while Novo faces patent expirations outside the US and pricing pressure from direct-to-consumer channels requiring significant price cuts.
• •Oral GLP-1 Competition: Novo's oral semaglutide pill generates 50,000 prescriptions weekly at launch, primarily through direct-to-consumer channels priced below Lilly's planned oral offering. Despite food and drink restrictions, patient demand remains strong, with most users switching from compounded versions rather than expanding the total patient population. HIMS announces $50 monthly compounded oral Wegovy, forcing further pricing pressure.
• •Psychedelic Drug Approval Politics: FDA initially included Compass Pathways' psilocybin treatment for treatment-resistant depression on the national priority voucher list, but the White House removed it hours before announcement despite RFK's public support for psychedelics. Compass negotiates alternative rolling submission pathway with FDA, allowing faster review than traditional process while avoiding political controversy that could undermine field credibility.
• •Kascevi Manufacturing Crisis: Only 60 patients globally receive Vertex's CRISPR sickle cell therapy two years post-approval because patients require three to five hospital visits for stem cell collection, with some needing two-week hospitalizations during sickle cell crises. Abnormally shaped sickle cells disrupt centrifuge color indicators used for cell selection, and harsh gene-editing process damages cells, requiring multiple collection cycles.
• •CRISPR Competitive Threat: Beam Therapeutics develops competing sickle cell therapy launching next year with easier cell collection, gentler manufacturing process, and potentially superior effectiveness. Genetics (formerly Bluebird Bio) already treats more patients than Vertex using less harsh manufacturing. Analyst Eric Schmidt predicts Beam will capture market leadership, threatening Vertex's decade-long investment in CRISPR technology development.